Close Menu

Amgen

Saga Investments has financial backing from Arch Venture Partners and Polaris Venture Partners, both of which had previously invested in Decode.

A number of events and trends that arose last year, including the increasing prevalence of direct-to-consumer genomics firms and PGx programs initiated by pharmacy services providers, might just make 2009 the year personalized medicine really started to take hold in the public's mind.

The finding highlights the importance of taking parental origin into account when conducting genome-wide association studies, and could provide a method for doing so by using data from a population obtained using Illumina microarrays.

The firm came under threat of delisting after filing for Chapter 11 bankruptcy protection.

Paired Ends: Jan 5, 2010

Premium

David Macdonald, Axel Nielsen

It was the second letter in as many months from Nasdaq to Decode, which has filed for bankruptcy protection in the US.

Since the FDA's 2005 preliminary concept paper on drug/diagnostic co-development, genomic advances have marched on, requiring the agency to revisit its now outdated guidance. A new white paper from the Personalized Medicine Coalition points out the areas requiring additional regulatory and evidentiary clarity from the agency.

According to one of the world's largest professional services firms, the trend toward tailoring drugs based on clinical factors and genomic variation will create opportunities and challenges for the pharmaceutical and biotech industries. PricewaterhouseCoopers estimates that the market for "a more personalized approach to health and wellness will grow to as much as $452 billion by 2015."

Decode's shares sank to a few pennies after the firm filed for bankruptcy protection. Meanwhile, Sequenom rose as it attempts rebound from a major setback in its Down syndrome test development program.

At a meeting hosted by the Partners HealthCare Center for Personalized Genetic Medicine last month, the events leading up to the re-labeling for colorectal cancer drugs Vectibix and Erbitux sparked discussion among participants about what Amgen and Bristol-Myers Squibb/ImClone knew about the drugs and when.

Pages

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.